Mechanisms of angiogenesis: Perspectives from antiangiogenic tumor therapies

Current Angiogenesis

Volumn 1, Issue 2, 2012, Pages 139-147

  Rice, Jeffrey J ^a   Gerwins, Pär ^b   Kilarski, Witold W ^a  

^a EPFL   (Switzerland)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Antiangiogenesis; Cancer; Healing; Intussusception; Tension; Vascularization

Indexed keywords

ERYTHROPOIETIN; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLOOD FLOW; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIAL PROGENITOR CELL; HUMAN; INTUSSUSCEPTIVE ANGIOGENESIS; LOOPING ANGIOGENESIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPROUTING ANGIOGENESIS; TUMOR VASCULARIZATION; VACUUM ASSISTED CLOSURE;

EID: 84875056275     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/2211552811201020139     Document Type: Review

References (94)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182-1186.
2. Cooke R. Dr. Folkman's War. Angiogenesis and the Struggle to Defeat Cancer. New York: Random House; 2001.
3. Hainsworth J, Heim W, Berlin J, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. Colorectal Cancer 2004; 350: 2335-2342.
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473(7347): 298-307.
5. Holstein SA, Hohl RJ. Therapeutic additions and possible deletions in oncology in 2011. Clin Pharmacol Ther 2012; 91: 15-17.
6. Borbath I, Lombard-bohas C, Valle J, et al. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med 2011; 364: 501-513.
7. Wells SA, Jr., Robinson BG, Gagel RF, et al. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. J Clin Oncol 2012; 30(2): 134-141.
8. Hamburg MA. Proposal to Withdraw Approval for the Breast Cancer Indication for AVASTIN (Bevacizumab). Docket No FDA- 2010-N-06212012.
9. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
10. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
11. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24: 3555-3561.
12. Beerepoot LV, Witteveen EO, Groenewegen G, et al. Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer: A Pharmacokinetic and Long-Term Safety Study Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer: A Pharmacokinetic and Long-Term Safety Study 1. Clin Cancer Res 2003; 9: 4025-4033.
13. Eisterer W, Jiang X, Bachelot T, et al. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther 2002; 5: 352-359.
14. Pawliuk R, Bachelot T, Zurkiya O, Eriksson A, Cao Y, Leboulch P. Continuous Intravascular Secretion of Endostatin in Mice from Transduced Hematopoietic Stem Cells. Gene Ther 2002; 5: 345-351.
15. Leboulch P. Setbacks for Endostatin. Science 2002; 295: 2198-2199.
16. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
17. Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22: 4683-4690.
18. Krüger A, Soeltl R, Sopov I, et al. Hydroxamate-Type Matrix Metalloproteinase Inhibitor Batimastat Promotes Liver Metastasis Advances in Brief Hydroxamate-Type Matrix Metalloproteinase Inhibitor Batimastat Promotes. Cancer 2001; 61(4): 1272-1275.
19. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
20. Langer R, Brem H, Falterman K, Klein M, Folkman J. Isolations of a cartilage factor that inhibits tumor neovascularization. Science 1976; 193(4247): 70-72.
21. Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 2010; 102: 859-865.
22. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M. Inhibition of the alpha-n integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002; 86(5): 788-795.
23. Alghisi GC, Ponsonnet L, Rüegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PloS One 2009; 4: e4449.
24. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009; 15: 392-400.
25. Weis SM, Stupack DG, Cheresh DA. Agonizing integrin antagonists? Cancer Cell 2009; 15: 359-361.
26. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
27. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
28. Kilarski WW, Bikfalvi A. Recent developments in tumor angiogenesis. Curr Pharm Biotechnol 2007; 8: 3-9.
29. Thoma R. Untersuchungen über die Histogenese und Histomechanik des Gefäßsystems. Stuttgart, Germany: F Enke; 1893.
30. Clark ER. Studies on the growth ofblood-vesse ls in the tail of the frog larva-By observation and experiment on the living animal. Am J Anat 1918; 23(1): 37-88.
31. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161(6): 1163-1177.
32. Isogai S, Lawson ND, Torrealday S, Horiguchi M, Weinstein BM. Angiogenic network formation in the developing vertebrate trunk. Development 2003; 130(21): 5281-5290.
33. Djonov VG, Kurz H, Burri PH. Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism. Dev Dyn 2002; 224(4): 391-402.
34. Benest AV, Augustin HG. Tension in the vasculature. Nat Med 2009; 15(6): 608-610.
35. Kilarski WW, Gerwins P. A new mechanism of blood vessel growth - hope for new treatment strategies. Discov Med 2009; 8: 23-27.
36. Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 2000; 50(1/2): 1-15.
37. Swift MR, Weinstein BM. Arterial-Venous Specification During Development. Circ Res 2009; 104(5): 576-588.
38. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998; 125(4): 725-732.
39. Zhong TP, Childs S, Leu JP, Fishman MC. Gridlock signalling pathway fashions the first embryonic artery. Nature 2001; 414(6860): 216-220.
40. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275(5302): 964-967.
41. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85(3): 221-228.
42. Zengin E, Chalajour F, Gehling UM, et al. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development 2006; 133(8): 1543-1551.
43. Grenier G, Scimè A, Le Grand F, et al. Resident endothelial precursors in muscle, adipose, and dermis contribute to postnatal vasculogenesis. Stem Cells 2007; 25(12): 3101-3110.
44. Tepper OM, Capla JM, Galiano RD, et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 2005; 105(3): 1068-1077.
45. Hagensen MK, Shim J, Thim T, Falk E, Bentzon JF. Circulating endothelial progenitor cells do not contribute to plaque endothelium in murine atherosclerosis. Circulation 2010; 121: 898-905.
46. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8(2): 79-88.
47. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-1159.
48. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bonemarrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
49. Ibrahim K, Christoph M, Strasser RH. Letter by Ibrahim et al regarding article Circulating endothelial progenitor cells do not contribute to plaque endothelium in murine atherosclerosis. Circulation 2010; 122: e566; author reply e7.
50. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003; 9: 789-795.
51. Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res 2010; 79: 217-223.
52. Bluff JE, Ferguson MWJ, O'Kane S, Ireland G. Bone marrowderived endothelial progenitor cells do not contribute significantly to new vessels during incisional wound healing. Exp Hematol 2007; 35: 500-506.
53. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82(1): 4-6.
54. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.
55. Clark ER, Clark EL. Microscopic observations of the growth of blood capillaries in the living mammal. Am J Anat 1939; 64: 251-299.
56. Fuelleborn F. Beiträge zur Entwicklung der Allantois der Vöogel. (Contributions for the development of the Bird Allantois). Berlin: Inaug Diss, Francke; 1895.
57. Mato M, Ookawara S. Ultrastructural observation on the tips of growing vascular cords in the rat cerebral cortex. Experientia 1982; 38(4): 499-501.
58. Auerbach R, Arensman R, Kubai L, Folkman J. Tumor-induced angiogenesis: lack of inhibition by irradiation. Int J Cancer 1975; 15(2): 241-245.
59. Gerwins P, Sköldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000; 34(3): 185-194.
60. Martino MM, Tortelli F, Mochizuki M, et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med 2011; 3(100): 100ra89.
61. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13(11): 1382-1397.
62. Fantin A, Vieira JM, Gestri G, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 2010; 116(5): 829-840.
63. Mahdavian Delavary B, van der Veer WM, van Egmond M, Niessen FB, Beelen RHJ. Macrophages in skin injury and repair. Immunobiology. 2011; 216(7): 753-762.
64. Ribatti D, Djonov V. Intussusceptive microvascular growth in tumors. Cancer Lett 2011; 316: 126-131.
65. Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn 2004; 231(3): 474-488.
66. Caduff JH, Fischer LC, Burri PH. Scanning electron microscope study of the developing microvasculature in the postnatal rat lung. Anat Rec 1986; 216(2): 154-164.
67. Burri PH, Tarek MR. A novel mechanism of capillary growth in the rat pulmonary microcirculation. Anat Rec 1990; 228(1): 35-45.
68. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007; 26(3-4): 489-502.
69. Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsh L. P38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 2002; 156: 149-160.
70. Crivellato E, Nico B, Vacca A, Djonov V, Presta M, Ribatti D. Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia 2004; 18(2): 331-336.
71. Patan S, Haenni B, Burri PH. Evidence for intussusceptive capillary growth in the chicken chorio-allantoic membrane (CAM). Anat Embryol 1993; 187(2): 121-130.
72. van Groningen JP, Wenink AC, Testers LH. Myocardial capillaries: increase in number by splitting of existing vessels. Anat Embryol 1991; 184(1): 65-70.
73. Semela D, Piguet A-C, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007; 46: 840-848.
74. Kilarski WW, Samolov B, Petersson L, Kvanta A, Gerwins P. Biomechanical regulation of blood vessel growth during tissue vascularization. Nat Med 2009; 15(6): 657-664.
75. Samolov B, Steen B, Seregard S, van der Ploeg I, Montan P, Kvanta A. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res 2005; 80(2): 159-166.
76. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3(5): 349-363.
77. Valluru M, Brown NJ, Cross SS, Reed MWR, Staton CA. Blood vessel characterization in human dermal wound repair and scarring. Br J Dermatol 2011; 165(1): 221-224.
78. Plikaitis CM, Molnar JA. Subatmospheric pressure wound therapy and the vacuum-assisted closure device: basic science and current clinical successes. Expert Rev Med Devices 2006; 3(2): 175-184.
79. Erba P, Ogawa R, Ackermann M, et al. Angiogenesis in wounds treated by microdeformational wound therapy. Ann Surg 2011; 253(2): 402-409.
80. Maes C, Kobayashi T, Selig MK, et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell 2010; 19(2): 329-344.
81. Mayer A, Höckel M, Horn L-C, Schmidberger H, Vaupel P. GLUT-1 staining of squamous cell carcinomas of the uterine cervix identifies a novel element of invasion. Int J Oncol 2011; 38(1):145-150.
82. Boardman KC, Swartz MA. Interstitial flow as a guide for lymphangiogenesis. Circ Res 2003; 92(7): 801-808.
83. Rutkowski JM, Swartz MA. A driving force for change: interstitial flow as a morphoregulator. Trends Cell Biol 2007; 17: 44-50.
84. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315(26): 1650-1659.
85. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003; 273(1/2): 83-101.
86. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer- Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaBDependent Manner. Cancer Cell 2010; 17: 135-147.
87. Hanahan D, Weinberg RA, Francisco S. The Hallmarks of Cancer Review University of California at San Francisco. Horm Res 2000; 100: 57-70.
88. Lopez JI, Kang I, You W-K, McDonald DM, Weaver VM. In situ force mapping of mammary gland transformation. Integr Biol 2011; 3: 910-921.
89. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8(8): 592-603.
90. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
91. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
92. Akakura N, Kobayashi M, Horiuchi I. Constitutive Expression of Hypoxia-inducible Factor-1 α Renders Pancreatic Cancer Cells Resistant to Apoptosis Induced by Hypoxia and Nutrient Deprivation. Cancer 2001; 61: 6548-6554.
93. Kurokohchi K, Deguchi A, Masaki T, et al. Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodoltargetting intervention radiology. World J Gastroenterol 2007; 13: 4398-4400.
94. Onishi T, Oishi Y, Goto H, Yanada S, Abe K. Histological features of hypovascular or avascular renal cell carcinoma: the experience at four university hospitals. Int J Clin Oncol 2002; 7: 159-164.